This study examined whether there is a difference in cancer symptom management effectiveness with cannabinoid medicine between men and women. It was published in the official Journal of the Multinational Association of Supportive Care in Cancer in October 2022.
The analysis comes from data collected from patients with cancer enrolled in the Quebec Cannabis Registry (Canada). Medical cannabis was initiated for the therapeutic management of cancer symptoms.
Included were 358 patients who completed the revised Edmonton Symptom Assessment System (ESAS-r) questionnaire at baseline and 3-month follow-up.
The results really show more than the author's objective concerning effectiveness differences between sexes. They show that cannabinoid medicine is perceived to be effective by both male and female cancer patients....for a LOT of cancer symptoms.
Interestingly, CBD-dominant products did not work well for either sex.
In the author's words:
Three months of MC [medical cannabis] therapy led to significant improvements in pain, tiredness, anxiety, and well-being in both sexes.
Only F [females] perceived improved drowsiness, nausea, lack of appetite, and shortness of breath
THC-dominant MC significantly reduced pain in M [males], whereas in F it diminished nausea and improved well-being
THC:CBD-balanced products significantly reduced pain, tiredness, anxiety, and improved well-being in M.
CBD-dominant products did not offer significant symptom relief in either sex.
The article abstract is here.